SUNPHARMA Sun Pharmaceuticals Industries Ltd Product Launches Announcement 2024 - Fibromun Agreement Sun Pharmaceutical has entered a global licensing agreement with Philogen to exclusively commercialize the anti-cancer product Fibromun, sharing post-commercialization profits in a 55:45 ratio, while Philogen completes clinical trials and regulatory pursuits..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Sun Pharmaceuticals Industries Ltd